Analysis of the US Retinal Therapeutics Market

Improvements in Administration and Efficacy Drive Growth

Regular Price: USD 4,950

Special Price USD 4,208

15% OFF

* Required Fields

Regular Price: USD 4,950

Special Price USD 4,208


Be the first to review this product

Since the introduction of Lucentis in 2006, vascular endothelial growth factor (VEGF) antagonists have become the clear choice in treatment for age related macular degeneration, diabetic macular edema, and retinal vein occlusion due to their high efficacy and safety. This research service evaluates the US market for the pharmaceutical management of AMD, DME, and RVO from 2009 to 2017, with 2012 as the base year. Segmentation by disorder is provided. Included are products on the market, products in development, and patient and revenue forecasts. Market challenges, drivers, and restraints are identified and assessed.

Table of Contents

Executive SummaryKey FindingsKey Findings (continued)Scope and SegmentationKey Questions This Study Will AnswerMarket Engineering MeasurementsMarket Engineering Measurements (continued)CEO’s PerspectiveKey Companies to WatchExecutive Summary—3 Big PredictionsMarket OverviewMarket Segmentation Compounding PharmaciesCompetitive PlaybookNew Market OpportunitiesNew Market Opportunities (continued)Drivers, Restraints, and Trends—Total Retinal Therapeutics MarketMarket DriversMarket RestraintsForecasts and Trends—Total Retinal Therapeutics MarketMarket Engineering MeasurementsMarket Engineering Measurements (continued)Market Engineering Measurements (continued)Forecast Assumptions and DefinitionsRevenue ForecastRevenue Forecast DiscussionPricing Trends and ForecastPricing Trends and Forecast DiscussionCompetitive EnvironmentCompetitive LandscapeMarketed Product Analysis Pipeline Analysis Pipeline Analysis (continued) Pipeline Analysis (continued) Market ShareMarket Share EvolutionMarket Share AnalysisTop CompetitorsTimeline of Key EventsPatent ExpirationsComparative Efficacy AnalysisComparative Efficacy Analysis DiscussionAMD Segment BreakdownAMD Segment—Market Engineering MeasurementsAMD Segment—Revenue ForecastAMD Segment—Revenue Forecast DiscussionAMD Segment—Prevalence and Treated Patients ForecastAMD Segment—Prevalence and Treated Patients Forecast DiscussionAMD Segment—Penetration AnalysisAMD Segment—Penetration Analysis (continued)DME Segment BreakdownDME Segment Market Engineering MeasurementsDME Segment—Revenue ForecastDME Segment—Revenue Forecast DiscussionDME Segment—Prevalence and Treated Patients ForecastDME Segment—Prevalence and Treated Patients Forecast DiscussionDME Segment—Penetration AnalysisDME Segment—Penetration Analysis (continued)RVO Segment BreakdownRVO Segment—Market Engineering MeasurementsRVO Segment—Revenue ForecastRVO Segment—Revenue Forecast Discussion RVO Segment—Prevalence and Treated Patients ForecastRVO Segment—Prevalence and Treated Patients DiscussionRVO Segment—Penetration AnalysisRVO Segment Penetration Analysis (continued)Key Companies to WatchCompanies to WatchRegeneronOphthotecAllerganThe Last WordThe Last Word—Three Big PredictionsThe Last Word—DiscussionThe Last Word—Discussion (continued)The Last Word—Discussion (continued)Legal DisclaimerAppendixDrivers ExplainedDrivers Explained (continued)Drivers Explained (continued)Drivers Explained (continued)Drivers Explained (continued)Restraints ExplainedRestraints Explained (continued)Restraints Explained (continued)Additional Sources of Information on Ophthalmic DisordersMarket Engineering MethodologyLearn More—Next Steps




Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.